Therapeutically Actionable Biomarkers in Lung Cancer: Clinical Applications for Nursing Practice

Join us for this dinner meeting series on biomarker-driven advances in NSCLC led by nurses, for nurses. You will gain up-to-date knowledge on molecular targets and biomarkers in NSCLC, as well as practical information on the implementation and management of targeted therapy in eligible patients.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


  • Introduction and Disease Overview
  • New and Emerging Predictive and Actionable Biomarkers for Targeted Therapies in NSCLC
  • Current and Emerging Biomarkers Predicting Response to Immune-Based Therapies to Guide Precision Treatment Decisions
  • Educating Patients on Their Treatment Options
  • Putting It All Together: Takeaway Resources and Discussion of Available Online Resources


Date / Time
Event Details


Beth Sandy, MSN, CRNP, OCN

Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Elizabeth S. Waxman, RN, MSN, ANP-BC

Nurse Practitioner
Thoracic/Head & Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Marianne Davies, DNP, CNS, ACNP-BC, AOCNP

Associate Instructor
Adult Specialty Program
Yale University School of Nursing
Nurse Practitioner
Medical Oncology
Smilow Cancer Hospital at Yale-New Haven
New Haven, Connecticut

Elizabeth Krueger, NP

Nurse Practitioner
Thoracic Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Goal Statement
The goal of this activity is to improve oncology nurses’ ability to educate and optimally care for patients with lung cancer who have actionable biomarkers.

Target Audience
This program is intended for oncology nurses and other healthcare professionals who care for patients with lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate new and emerging predictive biomarkers that guide precision treatment decisions in patients with NSCLC
  • Apply available clinical data and new therapeutic options for the individualized treatment of patients with actionable biomarkers
  • Discuss with patients the benefits and limitations of biomarker testing and targeted therapies, along with practical considerations such as comorbidities and adherence
  • Develop a proactive management plan for AEs associated with recently approved targeted agents and novel combinations


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Education

Designation of Credit

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.